AREG Expression

CI-VAR-00001036Explore in graph →CIViC 315

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Head and Neck Squamous Cell Carcinoma2
AREG Expression	Unspecified therapy	Predictive	B	Supports Resistance	3	rejected	EID847 47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tum… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC	civic
AREG Expression	Cetuximab + DocetaxelCombination	Predictive	B	Supports Resistance	2	accepted	EID846 47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tum… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Lung Non-Small Cell Carcinoma2
AREG Expression	Crizotinib	Predictive	B	Supports Resistance	2	accepted	EID781 Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions. PMID 23344087 · Kim et al., 2013 · Open in CIViC	civic
AREG Expression	Crizotinib	Predictive	D	Supports Resistance	3	accepted	EID780 A cell line (DFCI076) with EML1-ALK fusion and resistance mutation L1152R showed no response to ALK inhibition with crizotinib or TAE684. There was co-dependancy on AKT and EGFR-signaling and inhibiti… (full text at CIViC) PMID 21791641 · Sasaki et al., 2011 · Open in CIViC	civic

Malignant Colorectal Neoplasm2
AREG Expression	Cetuximab	Predictive	B	Supports Sensitivity Response	3	accepted	EID788 226 cetuximab-treated patients with colorectal cancer (CRC) were analyzed for mRNA expression (by qPCR) of EGFR and its ligands (EGF, TGFA, AREG and EREG). High AREG mRNA expression in KRAS wild type … (full text at CIViC) PMID 23374602 · Pentheroudakis et al., 2013 · Open in CIViC	civic
AREG Expression	Panitumumab	Predictive	B	Supports Sensitivity Response	4	accepted	EID1020 Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified… (full text at CIViC) PMID 26867820 · Seligmann et al., 2016 · Open in CIViC	civic